Skip to main
LGND
LGND logo

Ligand Pharmaceuticals (LGND) Stock Forecast & Price Target

Ligand Pharmaceuticals (LGND) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Ligand Pharmaceuticals Inc. has demonstrated robust cash inflows, which enable further deal-making and enhance its compounding business model, positioning the company advantageously within the smid-cap biotech sector. With anticipated strong product launches for Filspari and Ohtuvayre, along with ongoing revenue growth from stable contributors, the company's financial outlook appears promising. Additionally, Ligand's revenue streams from royalties, license payments, and sales of Captisol material bolster its financial stability and growth potential.

Bears say

The financial outlook for Ligand Pharmaceuticals is concerning due to several fundamental issues, including the potential underperformance of royalty assets and challenges related to the intellectual property durability of key products. Additionally, uncertainties surrounding the approval of clinical-stage royalty assets, less favorable future terms, and unexpected challenges faced by commercial partners contribute to a negative overall assessment. The company's recent model updates, which reflect incrementally lower net cash and a reduced weighted average cost of capital, further highlight these financial pressures.

Ligand Pharmaceuticals (LGND) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ligand Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ligand Pharmaceuticals (LGND) Forecast

Analysts have given Ligand Pharmaceuticals (LGND) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Ligand Pharmaceuticals (LGND) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $228, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $228, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ligand Pharmaceuticals (LGND)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.